Novo Integrated Sciences, Inc. Common Stock
NVOS
NVOS was delisted on the 5th of November, 2024.
6 hedge funds and large institutions have $386K invested in Novo Integrated Sciences, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$356K |
| 2 |
Goldman Sachs
New York
|
+$48.9K |
| 3 |
MS
Maven Securities
St Helier,
Jersey
|
+$34.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$10.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.34K |
Top Sellers
NVOS Hedge Fund Activity: Q1 2021 in Review
6 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Novo Integrated Sciences, Inc. Common Stock (NVOS) for Q1 2021, worth a combined $386K.
Buyers outnumbered sellers: 6 funds opened new NVOS positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Royal Bank of Canada, opening a new position worth an estimated $356K.
- 6 institutional investors held Novo Integrated Sciences, Inc. Common Stock (NVOS) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $386K of Novo Integrated Sciences, Inc. Common Stock stock for Q1 2021.
- 6 funds opened new Novo Integrated Sciences, Inc. Common Stock positions in Q1 2021 and 0 closed out, a net change of +6 holders.
- The largest Novo Integrated Sciences, Inc. Common Stock buyer in Q1 2021 was Royal Bank of Canada, an estimated $356K added.
Based on aggregated 13F filings for Q1 2021.